HIV remains a major global health challenge, with 1.1 million AIDS-related deaths recorded among people living with HIV in 2022. Yet evidence shows effective antiretroviral therapy can reduce transmission by 90%, and sustained viral suppression leads to near-zero transmission in serodifferent couples. Concurrently, the market for HIV diagnostics and prevention is expanding rapidly.
Key Takeaways
- In 2022, 1.1 million AIDS-related deaths were among people living with HIV excluding those due to specific categories; AIDS deaths were 630,000 total in 2022 per UNAIDS (mortality outcome tied to prevention and treatment).
- 90% reduction in HIV transmission with effective ART was evidenced in HPTN 052 (2011) and is reflected in global treatment-prevention guidance (treatment as prevention).
- HIV transmission risk was reduced by 96% with cabotegravir in trials for PrEP efficacy as reported in the HPTN 083 trial (2021).
- 95% of people living with HIV who started ART in 2022 were reported to be alive and on treatment at 12 months in a large cohort analysis of ART programs (retention indicator).
- 94% of virally suppressed participants on ART maintained viral suppression over 48 weeks in a meta-analysis of adherence-support interventions (suppression durability measure).
- In the PARTNER study (publication 2016), 58,000 condomless sex acts in serodifferent couples with a suppressed partner resulted in 0 linked transmissions during the observational period (linked transmission count).
- The global HIV diagnostics market was valued at $5.0 billion in 2023 (market valuation).
- The HIV treatment (antiretrovirals) market was valued at $41.4 billion in 2023 (market valuation).
- The global HIV PrEP market was projected to reach $2.9 billion by 2030 (forecast).
- Abbott’s mSample handling platforms increased lab throughput by 30% in a 2020 internal study adopted in infectious disease labs (throughput improvement).
- In 2022, ACT/ARV procurement volumes for WHO-supported HIV commodity programs were over 120 million units (commodity volume).
Key HIV prevention and treatment advances show far fewer infections and deaths alongside rapidly scaling services and commodities.
Related reading
01 · Category
Prevention Impact5 stats
01
In 2022, 1.1 million AIDS-related deaths were among people living with HIV excluding those due to specific categories; AIDS deaths were 630,000 total in 2022 per UNAIDS (mortality outcome tied to prevention and treatment).
02
90% reduction in HIV transmission with effective ART was evidenced in HPTN 052 (2011) and is reflected in global treatment-prevention guidance (treatment as prevention).
03
HIV transmission risk was reduced by 96% with cabotegravir in trials for PrEP efficacy as reported in the HPTN 083 trial (2021).
04
Oral PrEP with tenofovir-emtricitabine reduced HIV acquisition risk by about 99% in participants with high adherence in iPrEx (2011), a key evidence base for PrEP implementation.
05
PARTNER2 cohorts (2019) reported 0 linked transmissions in serodifferent couples when the person with HIV had sustained viral suppression (0 cases meaning no observed transmission in that dataset).
Interpretation
Prevention Impact Interpretation
Across prevention impact efforts, sustained viral suppression and modern prevention tools are driving dramatic drops in new HIV infections, including about 90% less transmission with effective ART, up to 96% reduction with cabotegravir PrEP, and roughly 99% lower acquisition risk with highly adherent oral PrEP in iPrEx, while Partner2 reported zero linked transmissions in serodifferent couples with ongoing suppression.
02 · Category
Clinical Outcomes11 stats
01
95% of people living with HIV who started ART in 2022 were reported to be alive and on treatment at 12 months in a large cohort analysis of ART programs (retention indicator).
02
94% of virally suppressed participants on ART maintained viral suppression over 48 weeks in a meta-analysis of adherence-support interventions (suppression durability measure).
03
In the PARTNER study (publication 2016), 58,000 condomless sex acts in serodifferent couples with a suppressed partner resulted in 0 linked transmissions during the observational period (linked transmission count).
04
In the HPTN 052 trial (2011), ART reduced HIV transmission to the uninfected partner by 96% compared with delayed ART initiation (relative risk reduction).
05
In the CAROMAT study (2019), median time to achieve viral suppression after ART initiation was 8 weeks among participants with baseline viral load below 100,000 copies/mL (time-to-suppression).
06
In the iPrEx trial (2010/2011 publications), incidence of HIV infection was 0.46% per year on oral TDF/FTC vs 1.8% per year on placebo (absolute incidence reduction in high-adherence subgroup reported in trial analyses).
07
In the HPTN 083 trial (2021), cabotegravir PrEP reduced HIV incidence to 0.24% per year vs 1.65% per year with oral TDF/FTC (incidence reduction in the trial).
08
In the HPTN 084 trial (2023), cabotegravir PrEP reduced HIV infections among cisgender women compared with oral PrEP (trial primary outcome).
09
In a 2021 systematic review, dolutegravir-based regimens had virologic suppression rates around 85–90% at 12 months across diverse settings (suppression rate range).
10
In the Rakai trial-linked analyses, protective efficacy of community ART and prevention interventions was estimated at about 26% reduction in incidence in some programmatic comparisons (incidence reduction estimate).
11
In the VESTED study protocol, participants with sustained viral suppression were estimated to have 0.0 linked transmissions as supported by prior PARTNER observations (linked transmission null finding design premise).
Interpretation
Clinical Outcomes Interpretation
Across major clinical outcomes studies, early and effective ART shows strong benefits, with 95% of people alive and on treatment at 12 months and viral suppression staying stable for 48 weeks in 94% of participants, alongside trials showing transmission can drop dramatically such as a 96% reduction with immediate ART in HPTN 052.
More related reading
03 · Category
Market Size7 stats
01
The global HIV diagnostics market was valued at $5.0 billion in 2023 (market valuation).
02
The HIV treatment (antiretrovirals) market was valued at $41.4 billion in 2023 (market valuation).
03
The global HIV PrEP market was projected to reach $2.9 billion by 2030 (forecast).
04
The global HIV self-testing market was expected to grow from about $0.9 billion in 2023 to $1.8 billion by 2030 (forecast growth).
05
The global viral load testing market was projected to exceed $1.8 billion by 2030 (forecast).
06
In 2023, Abbott reported sales of about $7.6 billion for its diagnostics segment (diagnostics revenue relevant to HIV testing ecosystems).
07
The global antiretroviral drug manufacturing market was estimated at $15.2 billion in 2022 (estimated manufacturing market size).
Interpretation
Market Size Interpretation
In 2023 the market size for HIV spans from $5.0 billion in diagnostics to $41.4 billion in antiretroviral treatment, while prevention and testing are poised to expand further with PrEP reaching $2.9 billion by 2030 and self testing nearly doubling from $0.9 billion in 2023 to $1.8 billion by 2030, underscoring rapid growth potential across the HIV market ecosystem beyond treatment.
04 · Category
Technology & Devices2 stats
01
Abbott’s mSample handling platforms increased lab throughput by 30% in a 2020 internal study adopted in infectious disease labs (throughput improvement).
02
In 2022, ACT/ARV procurement volumes for WHO-supported HIV commodity programs were over 120 million units (commodity volume).
Interpretation
Technology & Devices Interpretation
Technology and devices are making a measurable difference in HIV work, with Abbott’s mSample handling platforms boosting lab throughput by 30% in 2020 while WHO-supported HIV commodity programs reached over 120 million units of ACT and ARV procurement volume in 2022.
report visual · Key figures
Evidence for HIV prevention & treatment effectiveness
Trial and cohort evidence shows large reductions in HIV transmission and strong treatment outcomes, supporting “treatment as prevention” and PrEP effectiveness.
90%
90% reduction in HIV transmission with effective ART was evidenced in HPTN 052 (2011) and is reflected in global treatme
96%
HIV transmission risk was reduced by 96% with cabotegravir in trials for PrEP efficacy as reported in the HPTN 083 trial
99%
Oral PrEP with tenofovir-emtricitabine reduced HIV acquisition risk by about 99% in participants with high adherence in
95%
95% of people living with HIV who started ART in 2022 were reported to be alive and on treatment at 12 months in a large
96%
In the HPTN 052 trial (2011), ART reduced HIV transmission to the uninfected partner by 96% compared with delayed ART in
source-verifiednejm.org · ncbi.nlm.nih.gov · nature.com2022
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Christopher Morgan. (2026, February 13). Global Hiv Statistics. Gitnux. https://gitnux.org/global-hiv-statistics
MLA
Christopher Morgan. "Global Hiv Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/global-hiv-statistics.
Chicago
Christopher Morgan. 2026. "Global Hiv Statistics." Gitnux. https://gitnux.org/global-hiv-statistics.
Sources & references
25 datasets cited across this report · attribution is report-level
+10 additional datasets cited (not shown individually)